ClinicalTrials.gg
CompletedNCT01276106Updated May 22, 2018Results posted

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of AC-201, 25mg and AC-201, 50mg in Type 2 Diabetes Mellitus, sponsored by TWi Biotechnology, Inc.. Completed at 21 sites in 2 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-05-22.

Sponsored by TWi Biotechnology, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
259
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
851st of 2,957
259 · median 90
Started
2011
with 151 others
Phase 2
391 of 3,304
24 open now
Registered
1,041st of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 851st largest by enrollment of the 2,957 interventional ones that give a count, is one of 152 that started in 2011, is one of 391 in phase 2, and was the 1,041st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • AC-201
  • Interleukin 1 inhibitor
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understanding of the study procedures and agreement to participate in the study by giving written
  • Males and females age 20 to 75 years, inclusive
  • ≥7.5% and ≤10%
  • ≤45 kg/m2
  • FPG ≤270 mg/dL
  • Diagnosis of type 2 diabetes mellitus for ≥6 months
  • On a stable regimen of oral anti-diabetic medications for ≥3 months
  • Willingness to maintain stable diet and exercise throughout the study
  • Willingness to maintain current doses/regimens of vitamins and dietary supplements throughout the study
  • Female patients of and female partners of male patients must be willing to use adequate during the study. All females of childbearing potential must have a negative urine pregnancy test at screening.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes and/or history of ketoacidosis
  • History of diabetic neuropathy resulting in significant functional impairment and/or requiring active medical or surgical management, including chronic pain syndromes, gastroparesis, skin ulceration, or amputation
  • History of long-term therapy with insulin (>30 days) within 1 year of screening;
  • Pregnancy or lactation
  • Current treatment with any of the following medications within 2 months of screening
  • Anti inflammatory drugs, including chronic daily use of systemic (aspirin ≤325 mg per day is allowed)
  • IL-1 modulators: anakinra and rilonacept
  • drugs: TNF inhibitors and IL-6 monoclonal antibody
  • History of severe hypoglycemic episodes within 6 months of screening
  • to AC-201 or anthraquinone derivatives
  • Surgery within 30 days prior to screening
  • Serum creatinine >1.5 mg/dL for males or >1.4 mg/dL for females
  • Presence of cancer or history of cancer within the past 5 years other than basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix
  • Advanced stage heart failure: Class III or IV cardiac status or hospitalization for congestive heart failure
  • History of unstable angina, myocardial infarction, uncontrolled arrhythmias, cerebrovascular accident, , or any revascularization, including percutaneous transluminal coronary angioplasty, within 6 months of screening
  • Uncontrolled hypertension (defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg on ≥3 assessments at screening)
  • Known to be infected with (HIV)
  • History of acquired immune deficiency syndrome
  • History of TB, active TB (pulmonary, extra-pulmonary, or military), or a positive test for TB confirmed by a PA chest x-ray within 6 months prior to screening
  • History of acute infection with Epstein-Barr Virus (EBV), cytomegalovirus (CMV), or virus (HCV) within 4 weeks prior to screening
  • History of chronic active (not latent) virus, HCV, or CMV infection;
  • History of drug or alcohol abuse
  • >3 × the (ULN) or alanine aminotransferase >3 × ULN at screening
  • Total >1.5 × ULN at screening
  • Triglycerides >500 mg/dL at screening
  • Poor mental function or any other reason to expect patient difficulty in complying with the study requirements
  • Acute infections that may affect blood glucose control within 4 weeks prior to screening
  • Known bilateral renal artery stenosis, patient with a solitary kidney, or a post renal transplant
  • History of disease or collagen vascular disease
  • History of hyperthyroidism or hypocorticism
  • Participation in any AC-201 studies within 1 year prior to screening
  • Participation in an drug study within 30 days prior to screening
  • Any other serious diseases which, in the opinion of the investigator, might pose a risk to the patient or make participation not in the patient's best interest.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
259 participants (actual)

Study arms

  • Experimental
    AC-201, 25mg

    25mg BID for 24 weeks

    Drug: AC-201, 25mg

  • Experimental
    AC-201, 50mg

    50mg BID for 24 weeks

    Drug: AC-201, 50mg

  • Experimental
    AC-201, 75mg

    75mg BID for 24 weeks

    Drug: AC-201, 75mg

  • Placebo comparator
    Placebo

    Placebo BID for 24 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline

    For efficacy analyses, the primary analysis was at Week 24 Endpoint, defined as the last valid post-baseline measurement taken at or before Week 24. Efficacy results for treatment groups were considered statistically significant if change from baseline relative to placebo had p\<0.05.

    Time frame: 24 weeks

07

Results

Posted Nov 18, 2014

Participant flow

The participants were recruited in 21 study centers, which were located in 2 countries (USA and Taiwan)

Participant flow — Overall Study
MilestoneAC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlacebo
Started65646565
Completed53554952
Not completed1291613
Withdrew: Adverse event33113
Withdrew: Withdrawal by subject6316
Withdrew: Lack of efficacy0101
Withdrew: Lost to follow-up2110
Withdrew: Physician decision0011
Withdrew: Protocol violation1102
Withdrew: Insufficient therapeutic effects0020

Outcome measures

PrimaryChange in HbA1c From Baseline

For efficacy analyses, the primary analysis was at Week 24 Endpoint, defined as the last valid post-baseline measurement taken at or before Week 24. Efficacy results for treatment groups were considered statistically significant if change from baseline relative to placebo had p\<0.05.

Time frame:
24 weeks
Reported as:
Least squares mean · percentage points
Change in HbA1c From Baseline
percentage pointsAC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlacebo
Change in HbA1c From Baseline0.03 ± 0.123-0.07 ± 0.126-0.13 ± 0.1250.22 ± 0.123
Statistical analysis
  • AC-201, 75mg BID vs Placebo · ANCOVA · p = 0.044 (No adjustments for multiple comparisons were made and a value of p\<0.05 was considered statistically significant.) · Mean difference (final values): -0.35 · 95% CI -0.70 to -0.01
  • AC-201, 50mg BID vs Placebo · ANCOVA · p = 0.0979 (No adjustments for multiple comparisons were made and a value of p\<0.05 was considered statistically significant.) · Mean difference (final values): -0.29 · 95% CI -0.64 to 0.05
  • AC-201, 25mg BID vs Placebo · ANCOVA · p = 0.2643 (No adjustments for multiple comparisons were made and a value of p\<0.05 was considered statistically significant.) · Mean difference (final values): -0.20 · 95% CI -0.54 to 0.15

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC-201, 25mg BID—3/65 (4.6%)19/65 (29.2%)
AC-201, 50mg BID—2/64 (3.1%)25/64 (39.1%)
AC-201, 75mg BID—2/65 (3.1%)38/65 (58.5%)
Placebo—1/65 (1.5%)15/65 (23.1%)
Most frequent serious events
Most frequent serious events
EventAC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlacebo
Atrial FibrillationCardiac disorders0/651/640/650/65
Coronary Artery DiseaseCardiac disorders0/651/640/650/65
PneumoniaRespiratory, thoracic and mediastinal disorders0/651/640/650/65
HepatitisHepatobiliary disorders1/650/640/650/65
Renal MassRenal and urinary disorders1/650/640/650/65
Gastric Ulcer HemorrhageGastrointestinal disorders1/650/640/650/65
Breast CancerReproductive system and breast disorders0/650/641/650/65
Lumbar radiculopathyNervous system disorders0/650/641/650/65
Stress Urinary IncontenenceRenal and urinary disorders0/650/640/651/65
Most frequent other events
Most frequent other events
EventAC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlacebo
DiarrheaGastrointestinal disorders12/6510/6421/656/65
ChromatouriaRenal and urinary disorders2/655/6413/650/65
Upper respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders8/6510/644/656/65
NauseaGastrointestinal disorders3/653/644/651/65
HeadacheNervous system disorders1/652/644/652/65
Muscle SpasmsMusculoskeletal and connective tissue disorders0/650/644/652/65
Back PainNervous system disorders0/651/644/650/65

Baseline characteristics

Baseline was defined as the last measurement obtained on or before the first dose of the study medication.

Age, Continuous
Age, Continuous(years)AC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlaceboTotal
Mean56 ± 955 ± 957 ± 955 ± 856 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)AC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlaceboTotal
Female38332733131
Male27313832128
Region of Enrollment
Region of Enrollment(participants)AC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlaceboTotal
United States38373837150
Taiwan27272728109
HbA1c
HbA1c(%)AC-201, 25mg BIDAC-201, 50mg BIDAC-201, 75mg BIDPlaceboTotal
Mean8.4 ± 0.68.3 ± 0.78.5 ± 0.78.4 ± 0.78.4 ± 0.7
08

Study locations

21 sites
  • Catalina Research Institute, LLC
    Chino, California, United States
  • National Research Institute
    Los Angeles, California, United States
  • Clinical Research of South Florida
    Coral Gables, Florida, United States
  • Jacksonville Impotence Treatment Center
    Jacksonville, Florida, United States
  • Chicago Clinical Research Institute, Inc.
    Chicago, Illinois, United States
  • Clinical Investigation Specialists, Inc.
    Gurnee, Illinois, United States
  • Midwest Institute for Clinical Research, Inc.
    Indianapolis, Indiana, United States
  • L-MARC Research Center
    Louisville, Kentucky, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana, United States
  • Sterling Research Group, Ltd
    Cincinnati, Ohio, United States
  • PriMed Clinical Research
    Kettering, Ohio, United States
  • National Clinical Research-Richmond, Inc.
    Richmond, Virginia, United States
  • Rainier Clinical Research Center, Inc.
    Renton, Washington, United States
  • Changhua Christian Hospital
    Changhua, Taiwan
  • Cheng Ching General Hospital
    Taichung, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, Taiwan
  • Kuang Tien General Hospital
    Taichung, Taiwan
  • Cardinal Tien Hospital
    Taipei, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan
  • Taipei Medical University-Shuang Ho Hospital
    Taipei, Taiwan
  • Tri-Service General Hospital
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2011
First posted
Jan 13, 2011
Start
Jan 2011
Primary completionActual
Feb 2012
CompletionActual
Mar 2012
Results first posted
Nov 18, 2014
Last update
May 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01276106
Lead sponsor
TWi Biotechnology, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2011
Start date
Jan 2011
Primary completion
Feb 2012
Completion
Mar 2012
Results posted
Nov 18, 2014
Last update
May 22, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diacerein

Start the discussion